Scopus BioPharma Inc. Common Stock
SCPS
SCPS was delisted on the 16th of December, 2022.
14 hedge funds and large institutions have $1.14M invested in Scopus BioPharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.
7% more capital invested
Capital invested by funds: $1.07M → $1.14M (+$70K)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
7% less funds holding
Funds holding: 15 → 14 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$523K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$123K |
| 3 |
State Street
Boston,
Massachusetts
|
+$102K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$102K |
| 5 |
First Manhattan
New York
|
+$95.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$224K |
| 2 |
E
Ergoteles
New York
|
-$167K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$115K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$27.6K |
| 5 |
JP Morgan Chase
New York
|
-$22.3K |
SCPS Hedge Fund Activity: Q3 2021 in Review
14 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q3 2021, worth a combined $1.14M — up 6.5% from $1.07M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SCPS and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $523K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $224K sold.
- 14 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q3 2021, down from 15 in Q2 2021.
- Funds reported $1.14M of Scopus BioPharma Inc. Common Stock stock for Q3 2021, up 6.5% quarter-over-quarter.
- 6 funds opened new Scopus BioPharma Inc. Common Stock positions in Q3 2021 and 7 closed out, a net change of -1 holder.
- The largest Scopus BioPharma Inc. Common Stock buyer in Q3 2021 was Millennium Management, an estimated $523K added.
- The largest Scopus BioPharma Inc. Common Stock seller in Q3 2021 was Two Sigma Investments, an estimated $224K sold.
Based on aggregated 13F filings for Q3 2021.